Bolt Biotherapeutics, Inc. (BOLT) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 26K | 2.5M | 2.17M | 1.8M | 1.22M | 0 | 1.14M | 1.27M | 5.27M | 2.09M | 2.53M | 1.43M |
| Revenue Growth % | -97.87% | - | 90.1% | 41.49% | -76.83% | -100% | -54.87% | -11.03% | 188.83% | 48.05% | 19.7% | 2.87% |
| Cost of Goods Sold | 203K | 0 | 0 | 0 | 0 | 426K | 0 | 0 | 458K | 16.32M | 14.95M | 15.64M |
| COGS % of Revenue | 780.77% | - | - | - | - | - | - | - | 8.68% | 781.33% | 591.42% | 1091.7% |
| Gross Profit | -177K | 2.5M | 2.17M | 1.8M | 1.22M | -426K | 1.14M | 1.27M | 4.82M | -14.23M | -12.42M | -14.21M |
| Gross Margin % | -680.77% | 100% | 100% | 100% | 100% | - | 100% | 100% | 91.32% | -681.33% | -491.42% | -991.7% |
| Gross Profit Growth % | -114.48% | 686.85% | 90.1% | 41.49% | -74.63% | 97.01% | 109.18% | 108.97% | 137.63% | 7.78% | 26.32% | 18.92% |
| Operating Expenses | 7.42M | 8.11M | 9.87M | 11.01M | 13.34M | 15.24M | 17.58M | 23.87M | 21.91M | 5.53M | 5.76M | 5.62M |
| OpEx % of Revenue | 28553.85% | 324.2% | 455.14% | 610.53% | 1091.41% | - | 1541.1% | 1872.31% | 415.4% | 264.86% | 227.85% | 392.25% |
| Selling, General & Admin | 2.8M | 3.12M | 3.34M | 3.52M | 3.83M | 3.95M | 3.8M | 4.87M | 5.84M | 5.53M | 5.76M | 5.62M |
| SG&A % of Revenue | 10761.54% | 124.68% | 153.85% | 194.9% | 313.01% | - | 332.95% | 382.27% | 110.67% | 264.86% | 227.85% | 392.25% |
| Research & Development | 4.63M | 4.99M | 6.54M | 7.5M | 9.51M | 11.3M | 13.79M | 15.43M | 16.07M | 16.32M | 14.95M | 15.64M |
| R&D % of Revenue | 17792.31% | 199.52% | 301.29% | 415.63% | 778.4% | - | 1208.15% | 1210.43% | 304.72% | 781.33% | 591.42% | 1091.7% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1000K | 0 | -1000K | -1000K | -1000K |
| Operating Income | -7.6M | -5.61M | -7.7M | -9.21M | -12.12M | -15.67M | -16.44M | -22.6M | -17.09M | -19.77M | -18.18M | -19.83M |
| Operating Margin % | -29234.62% | -224.2% | -355.14% | -510.53% | -991.41% | - | -1441.1% | -1772.31% | -324.08% | -946.19% | -719.26% | -1383.95% |
| Operating Income Growth % | 37.26% | 64.23% | 53.15% | 59.24% | 29.12% | 20.73% | 9.57% | -13.94% | 7.18% | 6.06% | 18.63% | 13.99% |
| EBITDA | -7.4M | -5.35M | -7.41M | -8.86M | -11.72M | -15.24M | -16M | -22.14M | -16.63M | -19.3M | -17.72M | -19.37M |
| EBITDA Margin % | -28453.85% | -214% | -341.77% | -491.3% | -958.76% | - | -1402.54% | -1736.47% | -315.4% | -923.84% | -700.99% | -1351.99% |
| EBITDA Growth % | 36.86% | 64.9% | 53.68% | 59.97% | 29.57% | 21.02% | 9.69% | -14.28% | 7.32% | 6.22% | 19.11% | 14.47% |
| D&A (Non-Cash Add-back) | 203K | 255K | 290K | 347K | 399K | 426K | 440K | 457K | 458K | 467K | 462K | 458K |
| EBIT | -7.6M | -5.61M | -7.7M | -9.21M | -12.12M | -15.94M | -16.44M | -19.03M | -17.09M | -19.77M | -18.18M | -19.83M |
| Net Interest Income | 276K | 367K | 477K | 599K | 1.05M | 980K | 1.27M | 1.4M | 1.61M | 1.86M | 1.93M | 1.77M |
| Interest Income | 276K | 367K | 477K | 599K | 1.05M | 980K | 1.27M | 1.4M | 1.61M | 1.86M | 1.93M | 1.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 357K | -1.03M | 559K | 649K | 1.07M | -267K | 1.27M | 1.4M | 6.28M | 1.86M | 1.93M | 1.77M |
| Pretax Income | -7.24M | -6.63M | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M | -21.2M | -10.81M | -17.9M | -16.26M | -18.06M |
| Pretax Margin % | -27861.54% | -265.24% | -329.37% | -474.56% | -903.44% | - | -1330.06% | -1662.35% | -204.99% | -857.01% | -643.08% | -1260.08% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -7.24M | -6.63M | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M | -21.2M | -10.81M | -17.9M | -16.26M | -18.06M |
| Net Margin % | -27861.54% | -265.24% | -329.37% | -474.56% | -903.44% | - | -1330.06% | -1662.35% | -204.99% | -857.01% | -643.08% | -1260.08% |
| Net Income Growth % | 34.38% | 58.39% | 52.93% | 59.61% | -2.12% | 10.99% | 6.65% | -17.38% | 36.33% | 10.47% | 25.29% | 20.33% |
| Net Income (Continuing) | -7.24M | -6.63M | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M | -21.2M | -10.81M | -17.9M | -16.26M | -18.06M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.87 | -3.84 | -3.72 | -4.46 | -0.29 | -0.42 | -0.40 | -0.56 | -0.28 | -0.47 | -0.43 | -0.48 |
| EPS Growth % | -1234.48% | -814.29% | -830% | -696.43% | -3.57% | 10.64% | 6.98% | -16.67% | 31.71% | 6% | 25.86% | 20% |
| EPS (Basic) | -3.87 | -3.84 | -3.72 | -4.46 | -0.29 | -0.42 | -0.40 | -0.56 | -0.28 | -0.47 | -0.43 | -0.48 |
| Diluted Shares Outstanding | 1.87M | 1.87M | 1.92M | 1.92M | 38.34M | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M | 37.87M | 37.75M |
| Basic Shares Outstanding | 1.87M | 1.87M | 1.92M | 1.92M | 38.34M | 38.29M | 38.25M | 38.13M | 38.07M | 37.94M | 37.87M | 37.75M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |